Nov 2 (Reuters) - Fresenius FREn.DE has signed a biosimilars development agreement with China's WuXi Biologics 2269.HK, the German healthcare group said on Monday.
The agreement gives Fresenius exclusive access to up to 37 identified biosimilar candidates over the next decade, addressing more than €370 billion ($414 billion) in originator sales, it added.
($1 = 0.8948 euros)
Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk
